These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31773426)

  • 1. A Critique of Pharmacokinetic Calculators for Drug Dosing Individualization.
    Janković SM
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):157-162. PubMed ID: 31773426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unified pharmacokinetic approach to individualized drug dosing.
    Begg EJ; Chin PK
    Br J Clin Pharmacol; 2012 Mar; 73(3):335-9. PubMed ID: 21851378
    [No Abstract]   [Full Text] [Related]  

  • 3. Physiologically-Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study.
    Rowland Yeo K; Venkatakrishnan K
    Clin Pharmacol Ther; 2021 Jan; 109(1):51-54. PubMed ID: 33220063
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug Development.
    Polasek TM; Rayner CR; Peck RW; Rowland A; Kimko H; Rostami-Hodjegan A
    Clin Pharmacol Drug Dev; 2019 May; 8(4):418-425. PubMed ID: 30500115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualizing the use of medications in children: making Goldilocks happy.
    Leeder JS; Brown JT; Soden SE
    Clin Pharmacol Ther; 2014 Sep; 96(3):304-6. PubMed ID: 24926777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalised dosing of medicines for children.
    Al-Metwali B; Mulla H
    J Pharm Pharmacol; 2017 May; 69(5):514-524. PubMed ID: 28266713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supporting Precision Dosing in Drug Labeling.
    Neely M; Onufrak N; Scheetz MH; Avedissian S; Lakota E; Deitchman AN; Gonzalez D
    Clin Pharmacol Ther; 2021 Jan; 109(1):37-41. PubMed ID: 33111328
    [No Abstract]   [Full Text] [Related]  

  • 8. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualization of drug therapy: history, present state, and opportunities for the future.
    Lesko LJ; Schmidt S
    Clin Pharmacol Ther; 2012 Oct; 92(4):458-66. PubMed ID: 22948891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision dosing in clinical medicine: present and future.
    Polasek TM; Shakib S; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):743-746. PubMed ID: 30010447
    [No Abstract]   [Full Text] [Related]  

  • 12. Beyond Population-Level Targets for Drug Concentrations: Precision Dosing Needs Individual-Level Targets that Include Superior Biomarkers of Drug Responses.
    Polasek TM; Peck RW
    Clin Pharmacol Ther; 2024 Sep; 116(3):602-612. PubMed ID: 38328977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose individualization in PharmDIS-e+.
    Proost JH; Punt NC
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):451-8. PubMed ID: 14703950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized Drug Dosage - Closing the Loop.
    Tucker GT
    Pharm Res; 2017 Aug; 34(8):1539-1543. PubMed ID: 27943015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
    Pai MP
    Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Dosing: An Industry Perspective.
    Peck RW
    Clin Pharmacol Ther; 2021 Jan; 109(1):47-50. PubMed ID: 33107023
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.
    Langebrake C; Bernhardt F; Baehr M; Kröger N; Zander AR
    Int J Clin Pharm; 2011 Dec; 33(6):918-24. PubMed ID: 21960151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance to develop individual dose recommendations for patients on chronic hemodialysis.
    Gotta V; Dao K; Rodieux F; Buclin T; Livio F; Pfister M
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):737-752. PubMed ID: 28447486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based drug treatment for special patient populations through model-based approaches.
    Krekels EHJ; van Hasselt JGC; van den Anker JN; Allegaert K; Tibboel D; Knibbe CAJ
    Eur J Pharm Sci; 2017 Nov; 109S():S22-S26. PubMed ID: 28502674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
    Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
    Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.